Literature DB >> 17433743

Comparisons of EPR imaging and T1-weighted MRI for efficient imaging of nitroxyl contrast agents.

Ken-ichiro Matsumoto1, Michiko Narazaki, Hiroo Ikehira, Kazunori Anzai, Nobuo Ikota.   

Abstract

The resolution and signal to noise ratio of EPR imaging and T(1)-weighted MRI were compared using an identical phantom. Several solutions of nitroxyl contrast agents with different EPR spectral shapes were tested. The feasibility of T(1)-weighted MRI to detect nitroxyl contrast agents was described. T(1)-weighted MRI can detect nitroxyl contrast agents with a complicated EPR spectrum easier and quicker; however, T(1)-weighted MRI has less quantitative ability especially for lipophilic nitroxyl contrast agents, because T(1)-relaxivity, i.e. accessibility to water, is affected by the hydrophilic/hydrophobic micro-environment of a nitroxyl contrast agent. The less quantitative ability of T(1)-weighted MRI may not be a disadvantage of redox imaging, which obtains reduction rate of a nitroxyl contrast. Therefore, T(1)-weighted MRI has a great advantage to check the pharmacokinetics of newly modified and/or designed nitroxyl contrast agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17433743     DOI: 10.1016/j.jmr.2007.03.013

Source DB:  PubMed          Journal:  J Magn Reson        ISSN: 1090-7807            Impact factor:   2.229


  2 in total

Review 1.  Assessment of tissue redox status using metabolic responsive contrast agents and magnetic resonance imaging.

Authors:  Fuminori Hyodo; Benjamin P Soule; Ken-Ichiro Matsumoto; Shingo Matusmoto; John A Cook; Emi Hyodo; Anastasia L Sowers; Murali C Krishna; James B Mitchell
Journal:  J Pharm Pharmacol       Date:  2008-08       Impact factor: 3.765

2.  Synthesis, Stability and Relaxivity of TEEPO-Met: An Organic Radical as a Potential Tumour Targeting Contrast Agent for Magnetic Resonance Imaging.

Authors:  Maiju Soikkeli; Kaisa Horkka; Jani O Moilanen; Marjut Timonen; Jari Kavakka; Sami Heikkinen
Journal:  Molecules       Date:  2018-04-27       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.